Alector, Inc. Price Chart
Alector, Inc. 0Z2.F Financial and Trading Overview
| Alector, Inc. stock price | 5.8 EUR |
| Previous Close | 7.1 EUR |
| Open | 6.9 EUR |
| Bid | 6.9 EUR x 0 |
| Ask | 7 EUR x 0 |
| Day's Range | 6.9 - 6.9 EUR |
| 52 Week Range | 5.29 - 12.77 EUR |
| Volume | 90 EUR |
| Avg. Volume | 4 EUR |
| Market Cap | 485.87M EUR |
| Beta (5Y Monthly) | 0.778085 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.337 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44 EUR |
0Z2.F Valuation Measures
| Enterprise Value | -35351376 EUR |
| Trailing P/E | N/A |
| Forward P/E | -7.113402 |
| PEG Ratio (5 yr expected) | 13.33 |
| Price/Sales (ttm) | 3.8655965 |
| Price/Book (mrq) | 3.1420765 |
| Enterprise Value/Revenue | -0.281 |
| Enterprise Value/EBITDA | 0.256 |
Trading Information
Alector, Inc. Stock Price History
| Beta (5Y Monthly) | 0.778085 |
| 52-Week Change | -6.60% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.77 EUR |
| 52 Week Low | 5.29 EUR |
| 50-Day Moving Average | 6.47 EUR |
| 200-Day Moving Average | 7.78 EUR |
0Z2.F Share Statistics
| Avg. Volume (3 month) | 4 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 0 |
| Float | 62.01M |
| Short Ratio | N/A |
| % Held by Insiders | 11.03% |
| % Held by Institutions | 81.57% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -107.046% |
| Operating Margin (ttm) | -114.42% |
| Gross Margin | -66.48% |
| EBITDA Margin | -110.063% |
Management Effectiveness
| Return on Assets (ttm) | -10.55% |
| Return on Equity (ttm) | -59.72% |
Income Statement
| Revenue (ttm) | 125.69M EUR |
| Revenue Per Share (ttm) | 1.52 EUR |
| Quarterly Revenue Growth (yoy) | -32.39% |
| Gross Profit (ttm) | -76801000 EUR |
| EBITDA | -138340992 EUR |
| Net Income Avi to Common (ttm) | -134550000 EUR |
| Diluted EPS (ttm) | -0.337 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 669.33M EUR |
| Total Cash Per Share (mrq) | 8.03 EUR |
| Total Debt (mrq) | 42.18M EUR |
| Total Debt/Equity (mrq) | 23.05 EUR |
| Current Ratio (mrq) | 6.908 |
| Book Value Per Share (mrq) | 2.196 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -203968000 EUR |
| Levered Free Cash Flow (ttm) | -79015248 EUR |
Profile of Alector, Inc.
| Country | Germany |
| State | CA |
| City | South San Francisco |
| Address | 131 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 415 231 5660 |
| Website | https://www.alector.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 273 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Q&A For Alector, Inc. Stock
What is a current 0Z2.F stock price?
Alector, Inc. 0Z2.F stock price today per share is 5.8 EUR.
How to purchase Alector, Inc. stock?
You can buy 0Z2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alector, Inc.?
The stock symbol or ticker of Alector, Inc. is 0Z2.F.
How many shares does Alector, Inc. have in circulation?
The max supply of Alector, Inc. shares is 70.42M.
What is Alector, Inc. Price to Earnings Ratio (PE Ratio)?
Alector, Inc. PE Ratio is now.
What was Alector, Inc. earnings per share over the trailing 12 months (TTM)?
Alector, Inc. EPS is -0.337 EUR over the trailing 12 months.